Compare WATT & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WATT | BIVI |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 14.2M |
| IPO Year | 2014 | N/A |
| Metric | WATT | BIVI |
|---|---|---|
| Price | $5.97 | $1.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 45.5K | ★ 65.1K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,018,000.00 | N/A |
| Revenue This Year | $509.64 | N/A |
| Revenue Next Year | $210.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 600.23 | N/A |
| 52 Week Low | $3.67 | $1.25 |
| 52 Week High | $81.00 | $30.00 |
| Indicator | WATT | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 39.72 | 52.45 |
| Support Level | $5.92 | $1.45 |
| Resistance Level | $6.77 | $1.70 |
| Average True Range (ATR) | 0.50 | 0.10 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 14.18 | 75.56 |
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs, and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. The WPN technology provides a comprehensive suite of capabilities designed to power the next generation of wireless energy networks, seamlessly delivering power and data across diverse, battery-free device ecosystems. It enhances operational visibility, control, and intelligent business automation. Its products include Transmitter IC & Module, Receivers IC, Transmitter System, and Evaluation Kits.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.